A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician\'s choice of abiraterone acetate, enzalutamide, or docetaxel.
Epistemonikos ID: f04ec27f29081e33deb2fb3b1bac0297102a5ebf
First added on: Jun 21, 2022